Never miss an important update on your stock portfolio and cut through the noise. Over 7 million investors trust Simply Wall St to stay informed where it matters for FREE.

DexCom's latest analyst work shows a modest lift in the modelled fair value, with the price target figure moving from US$91.64 to US$94.12. This adjustment sits alongside mixed analyst commentary that balances positive Q2 2026 execution, new clinical data and guidance updates, and ongoing questions about valuation and sector sentiment. As you read on, you will see how these moving parts shape the current story around DexCom and how to keep track of future shifts in the narrative.

Stay updated as the Fair Value for DexCom shifts by adding it to your watchlist or portfolio . Alternatively, explore our Community to discover new perspectives on DexCom.

What Wall Street Has Been Saying

🐂 Bullish Takeaways

• Several firms including Citi, Argus, Raymond James, Deutsche Bank, UBS, TD Cowen, Stifel and Mizuho have raised DexCom price targets into a US$87 to US$105 range. This signals confidence in the stock's setup following recent Q2 updates.

• Analysts at Argus and TD Cowen highlight DexCom's continuous glucose monitoring clinical data and the CONNECT study as important supports for potential payer coverage expansion, including Medicare for Type 2 patients who are not on insulin.

• Raymond James and UBS point to strong margins, sensor rollout benefits, expanding reimbursement opportunities and the company's cash position as key positives that support long term growth potential.

• Citi and Deutsche Bank commentary refers to a robust product pipeline and easing concerns around the continuous glucose monitoring market, with some prior overhangs described as fading after DexCom's investor day.

🐻 Bearish Takeaways

• Truist and Mizuho describe a mixed setup for the broader medical technology sector, with investors still cautious on procedure volumes, capital spending and what might bring new money back into the group. This can affect sentiment around DexCom even with company specific positives.

Do your thoughts align with the Bull or Bear Analysts? Perhaps you think there's more to the story. Head to the Simply Wall St Community to discover more perspectives!

See how DexCom's fair value stacks up across multiple valuation models — not just analyst targets.

How This Changes the Fair Value For DexCom

• The estimated fair value moves from US$91.64 to US$94.12 in the updated DexCom model.

• The revenue growth assumption changes from about 11.14% to about 11.20%.

• The net profit margin assumption changes from about 21.49% to about 21.85%.

• The assumed future P/E multiple changes from about 26.1x to about 26.4x.

• The discount rate assumption changes from 7.45% to about 7.55%.